SEC Tracker
Get the app

SI-BONE SIBN

SI-BONE Q1 FY26: revenue $52.6M, up 11%; diluted EPS −$0.10

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers SI-BONE reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$52.6M+11% from $47.3M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$4.3MAgainst −$6.5M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.10Against −$0.15 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$33.5M−19% from $41.2M in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$2.4MAgainst −$4.9M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when SI-BONE files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  2. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
  3. Mimedx Group MDXG public float $719M, Jun 30, 2025
  4. Heartflow HTFL
  5. Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.